Early research suggests first immunotherapy for mesothelioma on the horizon

(American Society of Clinical Oncology) Malignant pleural mesothelioma or MPM is a rare cancer, but its incidence has been rising. This cancer is usually associated with asbestos exposure, and patients have a median life expectancy of only 13-15 months. All patients relapse despite initial chemotherapy, more than 50% of them within six months after stopping treatment. There are currently no effective therapeutic options for patients with MPM.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news